GET DAILY SIGNALSKyverna Therapeutics (KYTX): Analyst Targets Highlight Path to $30
Key Takeaways
- The central $30 target represents the arithmetic mean of five verified analyst price targets, rounded from a calculated mean of $30.40.
- Individual targets span a low of $25 from H.C. Wainwright to a high of $33 from Morgan Stanley and Wells Fargo, showing a notable range of views.
- With shares trading near $5.08, a move to $30 would imply upside of roughly 490%, a substantial gain by any measure.
- Support stems from positive registrational data in stiff person syndrome and plans for a Biologics License Application that could mark the first approved CAR T therapy for autoimmune disease.
- Primary risks include the lack of approved products or revenue, reliance on a small single-arm registrational dataset, and shares trading near 52-week lows despite the bullish targets.
- For more detail on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore the dedicated pages.
Analyst Price Targets and Consensus View
Five attributable analyst price targets were reviewed, producing an approximate range of $25 to $33 and a calculated average of $30.40, rounded to a $30 central target. H.C. Wainwright holds a $25 target, having raised it from $20 in May 2026. J.P. Morgan lowered its target from $30 to $29 in May 2026. Leerink Partners lifted its target from $25 to $32 in late 2025, while Morgan Stanley and Wells Fargo each maintain $33 targets. Collectively, the covering analysts describe the stock as a Buy or Overweight, with an overall Strong Buy-style tilt, though the wide $25-to-$33 spread signals meaningful disagreement about approval timing, commercial uptake, and valuation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares recently traded near $5.08, giving the company a market capitalization of roughly $315 million. The move to $30 implies upside of approximately 490%, which must be classified as very large. Kyverna Therapeutics, Inc. (KYTX) has no approved products or revenue and reported a GAAP net loss of about $38 million in its most recent quarter, with negative EPS. The path to a higher valuation therefore runs through clinical and regulatory execution: a rolling BLA submission for miv-cel in stiff person syndrome, where the registrational KYSA-8 study showed statistically significant improvements in mobility and disability with a manageable safety profile, and longer-term expansion into generalized myasthenia gravis and other indications.
What Could Support a Move Toward the Target
The central bull case rests on KYSA-8 data, in which a meaningful majority of patients achieved clinically meaningful improvement and some previously aid-dependent patients regained independent walking. The company has reported roughly $279 million in cash, which it has said should fund operations into 2028, and holds RMAT and orphan drug designations. If miv-cel becomes the first approved CAR T therapy for an autoimmune disease, the addressable market could extend well beyond SPS into gMG, lupus nephritis, and rheumatoid arthritis, supporting the multi-indication thesis embedded in higher analyst targets.
What Could Prevent the Target From Being Reached
The obstacles are substantial. The registrational evidence rests on a small, single-arm Phase 2 dataset, which carries regulatory and commercial risk. CAR T therapies require specialized treatment centers, and commercial uptake in rare autoimmune disease remains unproven. The stock trades near its 52-week low despite bullish targets, suggesting the market discounts execution risk, approval timing, and the possibility of dilution as the company funds commercialization. Any clinical setback, BLA delay, or adverse regulatory signal could weigh heavily on a pre-revenue company.
Technical Levels and Market Structure
The stock's 52-week range spans roughly $4.49 to $13.67, and shares are trading near the lower end of that band after a sustained decline, with a year-to-date loss approaching 45%. The prior 52-week high near $13.67 and the psychological $10 level represent notable overhead resistance zones, while the $4.49-to-$5.09 area has functioned as support. Long-term trend structure remains clearly negative, meaning any durable move toward the analyst targets would likely require a fundamental catalyst rather than momentum alone.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though firms may differ. For Kyverna Therapeutics, Inc. (KYTX), the most consequential items are the BLA submission and any FDA communication on miv-cel in SPS, additional KYSA-6 gMG data, updated rheumatoid arthritis and lupus nephritis results, quarterly cash burn, and any financing activity. Earnings releases and analyst target revisions around those events will also shape the stock's trajectory, though no definitive forecast is warranted. From what I see, this is important because timing around these milestones often determines whether targets get revisited.
Exploring AI-Powered Insights
I find Tickeron’s AI Daily Buy/Sell Signals particularly useful when monitoring names like this. The tool leverages AI to scan thousands of securities and flag potential buy or sell opportunities based on technical and market shifts. It has become a regular part of my workflow for staying on top of volatile biotech stocks without replacing core fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KYTX's RSI Oscillator climbs out of oversold territory
The RSI Indicator for KYTX moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 19 similar instances when the indicator left oversold territory. In 18 of the 19 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 33 cases where KYTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
Following a +12.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where KYTX advanced for three days, in 122 of 137 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
KYTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KYTX as a result. In 44 of 52 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for KYTX turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In 23 of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KYTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for KYTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. KYTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.823) is normal, around the industry mean (3.498). P/E Ratio (-1.671) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KYTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement